Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 12, Number 8—August 2006

Research

Antibody Response to Pneumocystis jirovecii

Kieran R. Daly*†, Laurence Huang‡, Alison Morris§, Judy Koch*†, Kristina Crothers‡¶, Linda Levin†, Shary Eiser‡, Supriya Satwah†, Patrizia Zucchi‡#, and Peter D. Walzer*†Comments to Author 
Author affiliations: *Veterans Affairs Medical Center, Cincinnati, Ohio, USA; †University of Cincinnati, Cincinnati, Ohio, USA; ‡University of California, San Francisco, California, USA; §University of Southern California, Los Angeles, California, USA; ¶Yale University School of Medicine, New Haven, Connecticut, USA; #University of Pavia, Pavia, Italy

Main Article

Table 4

Antibody levels to major surface glycoprotein A in Pneumocystis pneumonia (PCP) patients by history of PCP and week of observation*

Week Combined
No history of PCP
History of PCP
n Geometric mean (95% CI) n Geometric mean (95% CI) n Geometric mean (95% CI)
Baseline (0) 78 5.6 (3.9–7.9) 59 5.8 (3.9–8.7) 19 4.7 (2.1–10.5)
1–2 24 12.0 (6.7–21.4) 18 13.7 (7.0–26.8) 6 7.6 (1.2–47.4)
3–4 17 11.5 (5.2–25.3) 11 13.7 (4.3–43.5) 6 7.3 (1.1–48.9)
5–6 17 5.1 (2.3–11.3) 13 4.0 (1.9–8.2) 4 5.7 (0.2–207.9)

*n = no. patients who were observed at the specified follow-up time and at baseline. CI, confidence interval.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO